June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Ranibizumab treatment and visual acuity outcomes in the presence or absence of pigment epithelium detachments: an interim analysis of the LUMINOUS study
Author Affiliations & Notes
  • Adrian H Koh
    Ophthalmology Eye & Retina Surgeons, Camden Medical Centre, Singapore, Singapore
  • Boris Gekkiev
    Novartis Pharma AG, Basel, Switzerland
  • Ayan Das Gupta
    Novartis Pharma, Hyderabad, India
  • Sue Lacey
    Novartis Pharma AG, Basel, Switzerland
  • Footnotes
    Commercial Relationships Adrian H Koh, Allergan (C), Allergan (F), Carl Zeiss Meditec (C), Carl Zeiss Meditec (F), Heidelberg Engineering (C), Heidelberg Engineering (F), Novartis (C), Novartis (F); Boris Gekkiev, Novartis (E); Ayan Das Gupta, Novartis (E); Sue Lacey, Novartis (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1415. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Adrian H Koh, Boris Gekkiev, Ayan Das Gupta, Sue Lacey, ; Ranibizumab treatment and visual acuity outcomes in the presence or absence of pigment epithelium detachments: an interim analysis of the LUMINOUS study. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1415.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To determine if the presence or absence of pigment epithelium detachments (PED) has an impact on the visual acuity (VA) outcomes of patients with neovascular age-related macular degeneration (nAMD) treated with ranibizumab in the LUMINOUS study.

 
Methods
 

LUMINOUS (clinicaltrials.gov; NCT01318941) is a prospective, 5-year, global, observational, multicenter study aiming to evaluate long-term safety, effectiveness and treatment patterns of intravitreal ranibizumab 0.5 mg in routine clinical practice across all approved indications. Initiated in March 2011, LUMINOUS is designed to recruit a total of 30,000 patients, with a minimum follow-up period of 12 months. The influence of baseline PED status (as assessed by the investigator in the primary treated eye) on VA outcomes and injection requirement was analyzed separately in both treatment naïve patients and those who were previously treated with ranibizumab. The analysis was conducted on the observed data set that included patients who had a baseline and 12-month VA assessment.

 
Results
 

A total of 9,790 patients were recruited prior to March 2013, of whom 9,125 (93.2%) had nAMD; 1628 treatment naïve, 7454 previously treated with ranibizumab, 43 previously treated with other ocular treatments. Irrespective of baseline PED status, treatment naïve patients had lower mean baseline VA (±SD) ­[53.3 (18.24) and 53.7 (19.16) ETDRS letters] compared with those previously treated with ranibizumab [60.3 (17.23) and 59.6 (17.40) ETDRS letters]. At month 12, regardless of PED status at baseline, the mean VA (ETDRS letters) improved in treatment naïve patients (3.4 and 5.4) and was maintained in those previously treated with ranibizumab (-1.4 and -1.5, Table 1). These outcomes were achieved with a similar number of injections across all subgroups analyzed (4.3 to 4.8).

 
Conclusions
 

Irrespective of the presence or absence of PED, similar VA outcomes were attained at month 12 with nearly same numbers of ranibizumab injections in both treatment naïve patients and those previously treated with ranibizumab in nAMD.  

 
Table 1. One year visual acuity outcomes and treatment exposure
 
Table 1. One year visual acuity outcomes and treatment exposure

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×